AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9389277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 8174433 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (1200 micrograms/day)
Number of subjects: 9
Study 8174433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3659665 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 0
Study 3659665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30514630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% atropine eye drops
Number of subjects: 438
Study 30514630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% atropine eye drops
Number of subjects: 438
Study 30514630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drops
Number of subjects: 438
Study 30514630 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 438
Study 29188875 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched milk (2 x 0.4 L/d)
Number of subjects: 50
Study 29188875 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate drink (2 x 0.4 L/d)
Number of subjects: 50
Study 25803694 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based assent (n=60)
Number of subjects: 120
Study 25803694 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper assent with interspersed quiz questions (n=29)
Number of subjects: 120
Study 25803694 — intervention group
Group type: COMPARATOR
Intervention: Paper assent without interspersed quiz questions (n=31)
Number of subjects: 120
Study 25803694 — intervention group
Group type: COMPARATOR
Intervention: Full paper group (n=29 + n=31)
Number of subjects: 120
Study 23135367 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg)
Number of subjects: 19
Study 23135367 — intervention group
Group type: COMPARATOR
Intervention: Lactose (LEx, control)
Number of subjects: 19
Study 21752522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptic shock group (lactate ≥ 4mmol/L and normotension)
Number of subjects: 300
Study 21752522 — intervention group
Group type: COMPARATOR
Intervention: Overt shock group (sustained hypotension after fluid challenge)
Number of subjects: 300
Study 19254586 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 101
Study 19254586 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 101
Study 17299377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 137
Study 15116058 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil, 600 mg, twice daily for 7 days
Number of subjects: 20
Study 15116058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15116058 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 20
Study 11559645 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention for general practitioners
Number of subjects: 0
Study 11559645 — intervention group
Group type: COMPARATOR
Intervention: Control group (general practitioners in East Gloucestershire)
Number of subjects: 0
Study 9756237 — intervention group
Group type: EXPERIMENTAL
Intervention: Research-based practice
Number of subjects: 0
Study 9756237 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically based research paradigm
Number of subjects: 0
Study 8186051 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated hip prosthesis
Number of subjects: 0
Study 8186051 — intervention group
Group type: COMPARATOR
Intervention: Uncoated, cementless hip prosthesis
Number of subjects: 0
Study 3555944 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (100 mg/day for 2 months)
Number of subjects: 11
Study 3555944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29509266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 80
Study 29509266 — intervention group
Group type: COMPARATOR
Intervention: Control (hip arthroplasty and symptomatic/supportive treatment)
Number of subjects: 80
Study 27605607 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline (D2 agonist)
Number of subjects: 12
Study 27605607 — intervention group
Group type: COMPARATOR
Intervention: Pergolide (D1/D2 agonist)
Number of subjects: 12
Study 27605607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24464452 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild/minimal stimulation protocol of recombinant FSH (rFSH) combined with GnRH antagonist (Group A)
Number of subjects: 349
Study 24464452 — intervention group
Group type: COMPARATOR
Intervention: Standard long protocol of rFSH combined with GnRH agonist (Group B)
Number of subjects: 349
Study 23756569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy diet
Number of subjects: 12
Study 23756569 — intervention group
Group type: COMPARATOR
Intervention: Fermented dairy diet (yogurt plus cheese)
Number of subjects: 12
Study 23756569 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented dairy diet (butter, cream, ice cream)
Number of subjects: 12
Study 23756569 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat dairy products (fermented and non-fermented)
Number of subjects: 12
Study 20735258 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (Arm I)
Number of subjects: 322
Study 20735258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (Arm II)
Number of subjects: 322
Study 20735258 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine/abacavir (Arm III)
Number of subjects: 322
Study 18327626 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD)
Number of subjects: 290
Study 18327626 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 290
Study 18327626 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 290
Study 18327626 — intervention group
Group type: COMPARATOR
Intervention: BPD
Number of subjects: 290
Study 18327626 — intervention group
Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 290
Study 18327626 — intervention group
Group type: COMPARATOR
Intervention: AGB
Number of subjects: 290
Study 16484760 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based supervisor training on worksite mental health
Number of subjects: 189
Study 12699607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) via videoconferencing (VC)
Number of subjects: 28
Study 12699607 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) face-to-face (F2F)
Number of subjects: 28
Study 10720118 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fatty acids (SCFA) enema administered twice daily for 3 weeks
Number of subjects: 9
Study 10720118 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution administered twice daily for 3 weeks
Number of subjects: 9
Study 8737132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (200 mg on day 1 followed by 100 mg daily for 6 additional days)
Number of subjects: 0
Study 8737132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (200 mg on day 1 followed by 100 mg daily for 2 additional days)
Number of subjects: 0
Study 8737132 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (200 mg once daily for 7 days)
Number of subjects: 0
Study 1343113 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg dexfenfluramine (dF) twice daily for 3 days prior to glucose infusion; 30 mg dF 90 min before the test.
Number of subjects: 29
Study 1343113 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dexfenfluramine (dF) before the test.
Number of subjects: 29
Study 1343113 — intervention group
Group type: EXPERIMENTAL
Intervention: dF treatment in obese subjects for one month.
Number of subjects: 29
Study 1343113 — intervention group
Group type: EXPERIMENTAL
Intervention: dF treatment in obese subjects with relative fasting hyperinsulinemia (> 100 pmol/l).
Number of subjects: 29
Study 1343113 — intervention group
Group type: EXPERIMENTAL
Intervention: dF treatment in obese subjects with low fasting plasma insulin (< 100 pmol/l).
Number of subjects: 29
Study 1343113 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment.
Number of subjects: 29
Study 2857709 — intervention group
Group type: EXPERIMENTAL
Intervention: trimipramine
Number of subjects: 25
Study 2857709 — intervention group
Group type: COMPARATOR
Intervention: doxepin
Number of subjects: 25
Study 31442786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tub bathing
Number of subjects: 120
Study 31442786 — intervention group
Group type: COMPARATOR
Intervention: Sponge bathing
Number of subjects: 120
Study 29022125 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) alone
Number of subjects: 128
Study 29022125 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 128
Study 29022125 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) + Parent Training (PT)
Number of subjects: 128
Study 29022125 — intervention group
Group type: COMPARATOR
Intervention: Parent Training (PT) + Placebo
Number of subjects: 128
Study 26700705 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN) 3 × 10(6) IU subcutaneously 3 times a week for 4 weeks and 13-cis-retinoic acid (RA) 40 mg orally daily for 30 days during radiation therapy
Number of subjects: 209
Study 26700705 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 40 mg/m(2) weekly for 5 weeks during radiation therapy
Number of subjects: 209
Study 26700705 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 209
Study 26700705 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 209
Study 26700705 — intervention group
Group type: COMPARATOR
Intervention: Acute toxicities of chemoradiation
Number of subjects: 209
Study 24154987 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation (affirmation)
Number of subjects: 236
Study 24154987 — intervention group
Group type: COMPARATOR
Intervention: Self-affirmation manipulation (no affirmation)
Number of subjects: 236
Study 24154987 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention manipulation (implementation intention)
Number of subjects: 236
Study 24154987 — intervention group
Group type: COMPARATOR
Intervention: Implementation intention manipulation (no implementation intention)
Number of subjects: 236
Study 23098013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice volunteer program
Number of subjects: 0
Study 23098013 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (control group)
Number of subjects: 0
Study 20117403 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sST2 levels measured at baseline and at 12 and 24 weeks
Number of subjects: 100
Study 20117403 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sST2 levels
Number of subjects: 100
Study 20117403 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in sST2 levels
Number of subjects: 100
Study 18022679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute nicotine (7 mg patch for 45 min)
Number of subjects: 15
Study 15901750 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% ethanolic extract from the roots of Echinacea angustifolia, 2.5-mL dose
Number of subjects: 11
Study 12934777 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin 10 mg/d
Number of subjects: 790
Study 12934777 — intervention group
Group type: COMPARATOR
Intervention: Extended-release tolterodine 4 mg/d
Number of subjects: 790
Study 10822316 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50-100 mg/day (n = 15)
Number of subjects: 29
Study 10822316 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 2.5-10 mg/day (n = 14)
Number of subjects: 29
Study 8867163 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 3.75 mg
Number of subjects: 55
Study 8867163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 1518695 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy during clinical trial participation
Number of subjects: 0
Study 6712393 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of tobramycin plus cefamandole
Number of subjects: 64
Study 6712393 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted infusion of tobramycin plus cefamandole
Number of subjects: 64
Study 6712393 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of tobramycin
Number of subjects: 64
Study 6712393 — intervention group
Group type: COMPARATOR
Intervention: Interrupted infusion of tobramycin
Number of subjects: 64
Study 31730643 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Theory of Personality Intervention (ITPI)
Number of subjects: 858
Study 31730643 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 858
Study 28079236 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO beverage (12.5% maltodextrin)
Number of subjects: 20
Study 28079236 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-GLN beverage (12.5% maltodextrin plus 15 g GLN)
Number of subjects: 20
Study 26841875 — intervention group
Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy (IPT) + treatment as usual (TAU)
Number of subjects: 200
Study 26841875 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 200
Study 24220914 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT (+) group
Number of subjects: 165
Study 24220914 — intervention group
Group type: COMPARATOR
Intervention: FOBT (-) group
Number of subjects: 165
Study 22538183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis brief intervention
Number of subjects: 134
Study 22538183 — intervention group
Group type: EXPERIMENTAL
Intervention: Written cannabis brief intervention
Number of subjects: 134
Study 22538183 — intervention group
Group type: COMPARATOR
Intervention: Health controls
Number of subjects: 134
Study 20716619 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored decision aid (DA)
Number of subjects: 625
Study 20716619 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention comparison condition
Number of subjects: 625
Study 17563866 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, weekly docetaxel chemotherapy
Number of subjects: 1
Study 16340380 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 27
Study 16340380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11263614 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Cardiac Defibrillator (ICD)
Number of subjects: 491
Study 11263614 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (Amiodarone)
Number of subjects: 491
Study 9623426 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetics (1 ml kg‐1 of a mixture of 0.25% bupivacaine with epinephrine and 1% lidocaine in equal parts)
Number of subjects: 64
Study 9623426 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetics + fentanyl 1 microgram kg‐1
Number of subjects: 64
Study 9623426 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetics + clonidine 1.5 micrograms kg‐1
Number of subjects: 64
Study 9623426 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetics + fentanyl 0.5 microgram kg‐1 and clonidine 0.75 microgram kg‐1
Number of subjects: 64
Study 9623426 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetics (control group)
Number of subjects: 64
Study 9623426 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetics + additives (fentanyl or clonidine)
Number of subjects: 64
Study 9623426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (in any group)
Number of subjects: 64
Study 9623426 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (in any group)
Number of subjects: 64
Study 7522646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary mitoxantrone
Number of subjects: 41
Study 7522646 — intervention group
Group type: COMPARATOR
Intervention: Intracavitary bleomycin
Number of subjects: 41
Study 3830246 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 to 0.88 mg daily
Number of subjects: 10
Study 29289332 — intervention group
Group type: EXPERIMENTAL
Intervention: 100μg levothyroxine sodium tablet once daily for 6 months
Number of subjects: 50
Study 29289332 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet dissolution rate (BP/EP 2014 & USP 2014)
Number of subjects: 50
Study 27280850 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 624
Study 27280850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 624
Study 25062861 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visits via web‐based video conferencing
Number of subjects: 13
Study 23224567 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment followed by balloon treatment (group 1)
Number of subjects: 42
Study 23224567 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon treatment (group 2)
Number of subjects: 42
Study 23224567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 21590260 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-velocity ramps
Number of subjects: 0
Study 21590260 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-cycle sinusoids
Number of subjects: 0
Study 21590260 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration segments (240 ms)
Number of subjects: 0
Study 21590260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency components associated with short duration segments
Number of subjects: 0
Study 18754987 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal home visiting interventions (not specifically designed to address intimate partner violence)
Number of subjects: 0
Study 18754987 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting interventions addressing intimate partner violence in nonperinatal population groups
Number of subjects: 0
Study 18754987 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal home visiting programs with specific intimate partner violence interventions
Number of subjects: 0
Study 17058610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar resection (Olympus ch 26, 30 degrees)
Number of subjects: 45
Study 17058610 — intervention group
Group type: COMPARATOR
Intervention: Monopolar resection (Storz Ch 26, 30 degrees)
Number of subjects: 45
Study 17058610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 12928051 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐174 C allele in the promoter region of IL‐6 gene
Number of subjects: 0
Study 12928051 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐174 CC genotype
Number of subjects: 0
Study 12928051 — intervention group
Group type: EXPERIMENTAL
Intervention: D allele of VNTR
Number of subjects: 0
Study 12928051 — intervention group
Group type: COMPARATOR
Intervention: VNTR C allele
Number of subjects: 0
Study 12928051 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐174 CC and VNTR DD genotypes
Number of subjects: 0
Study 10843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 57
Study 10843430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 9596934 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor scoring model for STD
Number of subjects: 1656
Study 8561526 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 377
Study 8561526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 6605565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 20 mg/kg once daily for four days
Number of subjects: 1467
Study 6605565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (other regimens)
Number of subjects: 1467
Study 6605565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1467
Study 6605565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (for contacts younger than age five)
Number of subjects: 1467
Study 31362674 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 136
Study 31362674 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 136
Study 29793698 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (group R)
Number of subjects: 30
Study 29793698 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group NS)
Number of subjects: 30
Study 26856213 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative Dyspnea Severity Score (pDS) during upright with O2, upright without O2, and supine without O2 assessments.
Number of subjects: 230
Study 26856213 — intervention group
Group type: COMPARATOR
Intervention: Dyspnea Visual Analog Scale (DVAS)
Number of subjects: 230
Study 26856213 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen withdrawal and supine provocation
Number of subjects: 230
Study 26856213 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise provocation
Number of subjects: 230
Study 24557087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/propofol regimen (group SP)
Number of subjects: 160
Study 24557087 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane regimen (group S)
Number of subjects: 160
Study 24557087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 22344040 — intervention group
Group type: EXPERIMENTAL
Intervention: BARC bleeding definition
Number of subjects: 12459
Study 22344040 — intervention group
Group type: COMPARATOR
Intervention: TIMI bleeding definition
Number of subjects: 12459
Study 22344040 — intervention group
Group type: COMPARATOR
Intervention: REPLACE-2 bleeding definition
Number of subjects: 12459
Study 22344040 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 12459
Study 19743543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (500 mg to 1000 mg twice a day) added to ongoing amlodipine therapy
Number of subjects: 1388
Study 19743543 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 1388
Study 19743543 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (calcium channel blocker)
Number of subjects: 1388